Back to News
Market Impact: 0.3
Abeona Therapeutics (ABEO) Highlights FDA Approval Of FAYUVI Gene Therapy For MPS IIIA
Source: Nasdaq
Healthcare & Biotech
The FDA approved Ultragenyx Pharmaceutical's FAYUVI (rebisufligene etisparvovec-hopf/UX111) to treat Sanfilippo syndrome type A (MPS IIIA). Abeona Therapeutics publicly congratulated Ultragenyx on the approval, which represents a positive regulatory milestone in rare-disease gene therapy.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.55
Ticker Sentiment
ABEO0.10
RARE0.85
More News
- Canaccord raises Ultragenyx stock price target on gene therapy approval
- Cantor Fitzgerald raises Ultragenyx stock price target on gene therapy approval
- Anthropic quietly sets up biology lab as it ramps AI drug program: Reuters
- Activist Jana Pushes Cooper Cos. to Replace CEO, Board Chair
- ‘No one knows what is in these deals’: Trump set to announce new Medicaid drug pricing model amid affordability concerns
- Theravance Biopharma shareholders approve merger with Zymeworks
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- 2026 Global Markets Outlook: Asset Allocation After the Great Disconnect
- Fintool Alternatives After the Microsoft Acquisition